Trial Profile
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Mesothelioma; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CONFIRM
- 01 Feb 2024 Results evaluating the cost-effectiveness of nivolumab compared to placebo for relapsed malignant mesotheliomas from the perspective of the Chinese healthcare system, by developing Markov model was developed based on data from this study, published in the International Journal of Clinical Pharmacy
- 22 Nov 2023 Results of cost-effectiveness of nivolumab compared to placebo based on data from this study, published in the International Journal of Clinical Pharmacy
- 06 Jun 2023 Primary endpoint (Progression free survival (modified RECIST or RECIST 1.1)) has been met, according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.